The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
30
Cannabis is administered three times daily during the active cannabis treatment period.
Matched placebo cannabis is administered three times daily during the placebo treatment period.
Intranasal opioid agonists are administered during sample and self-administration sessions
University of Kentucky Center on Drug and Alcohol Research
Lexington, Kentucky, United States
Number of Opioid Self-Administration Trials Completed
Number of drug-choice trials completed for intranasal opioid agonists during self-administration sessions.
Time frame: Up to 6.5 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Oral opioid agonist maintenance doses are administered four times daily throughout study participation.